About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
April 2019 M T W T F S S « Mar 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
My Favorite Dogs
Category Archives: DTC Advertising
As is well known, FDA's DDMAC has stubbornly refused to deliver any guidance for industry and for advertisers on what is and is not acceptable in communications on the Internet. Instead, the agency has repeatedly stated that it is not … Continue reading
Last week, the New York Times carried an article "FDA Rules on Ads Sow Confusion as Applied to the Web" that addresses the call by the agency to issue 14 letters regarding 45 brands based on the lack of risk … Continue reading
Yesterday I had the good fortune to participate on a panel staged at the National DTC Perspectives Conference held here in Washington. The conference was impressive not only because of the size and scope of the turnout – hundreds … Continue reading
This week it was announced that a senior fellow from the office of Senator Edward Kennedy would be heading back to FDA as a senior counselor to Dr. Joshua Sharfstein where it is reported that the FDA Office of Legislative … Continue reading
Reuters carried a report yesterday confirming not only that a moratorium on Direct-to-Consumer (DTC) advertising is likely to be introduced in the next Congress, but is going to be broached by Congressman Henry Waxman, the new Chair of the House … Continue reading